Friday, 16 October 2026European Markets

BELSHIPS Stock Bullish Momentum With A 9.38% Jump On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with BELSHIPS (BELCO.OL) jumping 9.38% to kr21.05 on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0% to kr1,412.36, following the last session's upward trend on what was a somewhat positive trend exchanging session today.

BELSHIPS's last close was kr19.24, 13.53% below its 52-week high of kr22.25.

About BELSHIPS

Belships ASA owns and operates dry bulk ships worldwide. It operates through Belships and Lighthouse Navigation segments. The company operates a fleet of 38 modern Supra/Ultramax bulk carriers, including newbuildings. It also provides technical, crewing, port agency, and logistical services. The company was founded in 1918 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, BELSHIPS has a trailing twelve months EPS of kr2.45.

PE Ratio

BELSHIPS has a trailing twelve months price to earnings ratio of 8.59. Meaning, the purchaser of the share is investing kr8.59 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.41%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 50.8%, now sitting on 614.13M for the twelve trailing months.

Moving Average

BELSHIPS's worth is way higher than its 50-day moving average of kr17.17 and way above its 200-day moving average of kr17.20.

More news about BELSHIPS (BELCO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com